+

WO2012121958A3 - Combination - Google Patents

Combination Download PDF

Info

Publication number
WO2012121958A3
WO2012121958A3 PCT/US2012/027177 US2012027177W WO2012121958A3 WO 2012121958 A3 WO2012121958 A3 WO 2012121958A3 US 2012027177 W US2012027177 W US 2012027177W WO 2012121958 A3 WO2012121958 A3 WO 2012121958A3
Authority
WO
WIPO (PCT)
Prior art keywords
eltrombopag
suitably
antibody
administration
another embodiment
Prior art date
Application number
PCT/US2012/027177
Other languages
French (fr)
Other versions
WO2012121958A2 (en
Inventor
Andres BRAINSKY
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of WO2012121958A2 publication Critical patent/WO2012121958A2/en
Publication of WO2012121958A3 publication Critical patent/WO2012121958A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates generally to the use of eltrombopag in combination with an anti-CD20 antibody to treat thrombocytopenia, suitably immune thrombocytopenia purpura. In one embodiment, the present invention relates a method of treating, thrombocytopenia, suitably immune thrombocytopenia purpura, suitably rituximab refractory immune thrombocytopenia purpura, in a human patient, comprising the step of administering to the patient an anti-CD20 antibody in combination with eltrombopag, suitably eltrombopag olamine. In one embodiment, the administration is simultaneous. In another embodiment, the administration is sequential in which eltrombopag, suitably eltrombopag olamine is administered first. Yet in another embodiment, an anti-CD20 antibody is administered first. In yet in another embodiment, administration of an antiCD20 antibody and eltrombopag, suitably eltrombopag olamine is staggered.
PCT/US2012/027177 2011-03-08 2012-03-01 Combination WO2012121958A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161450289P 2011-03-08 2011-03-08
US61/450,289 2011-03-08

Publications (2)

Publication Number Publication Date
WO2012121958A2 WO2012121958A2 (en) 2012-09-13
WO2012121958A3 true WO2012121958A3 (en) 2014-05-01

Family

ID=46798701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/027177 WO2012121958A2 (en) 2011-03-08 2012-03-01 Combination

Country Status (1)

Country Link
WO (1) WO2012121958A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271658A1 (en) * 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
US7160870B2 (en) * 2000-05-25 2007-01-09 Smithkline Beecham Corporation Thrombopoietin mimetics
US20100129352A1 (en) * 2007-05-03 2010-05-27 Muller Francis X Novel pharmaceutical composition
WO2010099019A1 (en) * 2009-02-24 2010-09-02 Alexion Pharmaceuticals, Inc. Antibodies containing therapeutic tpo/epo mimetic peptides
US20100323965A1 (en) * 2006-12-01 2010-12-23 Stategics, Inc. Thrombopoietin Mimetics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160870B2 (en) * 2000-05-25 2007-01-09 Smithkline Beecham Corporation Thrombopoietin mimetics
US20050271658A1 (en) * 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
US20100323965A1 (en) * 2006-12-01 2010-12-23 Stategics, Inc. Thrombopoietin Mimetics
US20100129352A1 (en) * 2007-05-03 2010-05-27 Muller Francis X Novel pharmaceutical composition
WO2010099019A1 (en) * 2009-02-24 2010-09-02 Alexion Pharmaceuticals, Inc. Antibodies containing therapeutic tpo/epo mimetic peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAM.: "Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.", J ONCOL PHARM PRACTICE., vol. 16, June 2010 (2010-06-01), pages 89 - 103, Retrieved from the Internet <URL:http://opp.sagepub.com/contenUl6/2/89.long> [retrieved on 20120523] *
RHODES ET AL.: "Current status of thrombopoietic agents.", EXPERT REV. HEMATOL., vol. 3, April 2010 (2010-04-01), pages 217 - 225, Retrieved from the Internet <URL:http://www.expert-reviews.com/doi/abs/10.1586/ehm.10.8?urlver-Z39.88-2003&rfrid=ori:rid:crossref.org&rfr-dat=cr_pub%3dpubmed> [retrieved on 20120523] *
SALAMA.: "Current treatment options for primary immune thrombocytopenia.", EXPERT REV. HEMATOL., vol. 4, February 2011 (2011-02-01), pages 107 - 118, Retrieved from the Internet <URL:http://www.expert-reviews.com/doi/abs/10.1586/ehm.10.76?urlver--Z39.88-20038rfrid=ori:rid:crossref.org&rfr-dat=cr_pub%3dpubmed> [retrieved on 20120523] *

Also Published As

Publication number Publication date
WO2012121958A2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
EA201490004A1 (en) BIFIDOBACTERIUM LACTIS BL-04 APPLICATION FOR TREATMENT OF RESPIRATORY DISEASES
MX2019002669A (en) Methods of treating behavioral symptoms of neurological and mental disorders.
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
HK1198869A1 (en) Combination treatments for hepatitis c
MY199027A (en) Method for treating or preventing ophthalmological conditions
WO2011107750A3 (en) Delayed prolonged drug delivery
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
MX362626B (en) Methods of treating pediatric patients using dexmedetomidine.
MX2015007147A (en) A method of reducing brain amyloid plaques using anti-a㟠antibodies.
MX2015014773A (en) Anti-cancer treatments with anti-egfr antibodies having a low fucosylation.
WO2012093258A3 (en) Irf5- related treatment and screening
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
MY158195A (en) Activation of innate and adaptive immune responses by a ginseng extract
WO2012138768A3 (en) Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
HK1218251A1 (en) Treatment of multiple sclerosis with laquinimod
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
NZ720273A (en) Preparations and methods for treating a gd2 positive cancer
HK1225972A1 (en) Use of laquinimod to delay huntington&#39;s disease progression
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12754278

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12754278

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014001762

Country of ref document: CL

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载